First-in-human administration of [(161)Tb]Tb-SibuDAB and comparative dosimetry with standard [(177)Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study
作为 PROGNOSTICS Ia 期研究的一部分,首次在人体内使用 [(161)Tb]Tb-SibuDAB,并与标准 [(177)Lu]Lu-PSMA-I&T 进行剂量比较。
期刊:European Journal of Nuclear Medicine and Molecular Imaging
影响因子:7.6
doi:10.1007/s00259-024-07009-w
Chirindel, Alin; Nicolas, Guillaume P; Westerbergh, Frida; McDougall, Lisa; Schmid, David E; Geistlich, Susanne; Tschan, Viviane J; Busslinger, Sarah D; Fokkema, Angelique; Aceto, Nicola; Bernhardt, Peter; van der Meulen, Nicholas P; Müller, Cristina; Wild, Damian; Schibli, Roger